What is the indication of Efpeglenatide? Exploring its Potential in Diabetes and Cardiovascular Health
•
4 min read
Based on recent clinical trial findings, Efpeglenatide, an investigational glucagon-like peptide-1 receptor agonist (GLP-1 RA), has demonstrated significant improvements in glycemic control and body weight loss for patients with type 2 diabetes (T2D). The drug’s potential indications extend beyond blood sugar management, showing promising results for reducing cardiovascular and renal risks in high-risk patient populations.
